Literature DB >> 15502845

Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model.

Lene Uhrbom1, Edward Nerio, Eric C Holland.   

Abstract

Bioluminescence imaging has previously been used to monitor the formation of grafted tumors in vivo and measure cell number during tumor progression and response to therapy. The development and optimization of successful cancer therapy strategies may well require detailed and specific assessment of biological processes in response to mechanistic intervention. Here, we use bioluminescence imaging to monitor the cell cycle in a genetically engineered, histologically accurate model of glioma in vivo. In these platelet-derived growth factor (PDGF)-driven oligodendrogliomas, G1 cell-cycle arrest is generated by blockade of either the PDGF receptor or mTOR using small-molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502845     DOI: 10.1038/nm1120

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  51 in total

1.  Bioluminescence imaging of Smad signaling in living mice shows correlation with excitotoxic neurodegeneration.

Authors:  Jian Luo; Amy H Lin; Eliezer Masliah; Tony Wyss-Coray
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-16       Impact factor: 11.205

2.  The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats.

Authors:  Chengkai Dai; Yelena Lyustikman; Alan Shih; Xiaoyi Hu; Gregory N Fuller; Marc Rosenblum; Eric C Holland
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 3.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

4.  NG2 cells in white matter but not gray matter proliferate in response to PDGF.

Authors:  Robert A Hill; Kiran D Patel; Jelena Medved; Alex M Reiss; Akiko Nishiyama
Journal:  J Neurosci       Date:  2013-09-04       Impact factor: 6.167

Review 5.  Illuminating cancer systems with genetically engineered mouse models and coupled luciferase reporters in vivo.

Authors:  Brandon Kocher; David Piwnica-Worms
Journal:  Cancer Discov       Date:  2013-04-12       Impact factor: 39.397

6.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Authors:  Stephen M Wiesner; Stacy A Decker; Jon D Larson; Katya Ericson; Colleen Forster; Jose L Gallardo; Chunmei Long; Zachary L Demorest; Edward A Zamora; Walter C Low; Karen SantaCruz; David A Largaespada; John R Ohlfest
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

7.  Novel dual-reporter preclinical screen for antiastrocytoma agents identifies cytostatic and cytotoxic compounds.

Authors:  Jessica J Hawes; John D Nerva; Karlyne M Reilly
Journal:  J Biomol Screen       Date:  2008-07-29

8.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Authors:  David Akhavan; Alexandra L Pourzia; Alex A Nourian; Kevin J Williams; David Nathanson; Ivan Babic; Genaro R Villa; Kazuhiro Tanaka; Ali Nael; Huijun Yang; Julie Dang; Harry V Vinters; William H Yong; Mitchell Flagg; Fuyuhiko Tamanoi; Takashi Sasayama; C David James; Harley I Kornblum; Tim F Cloughesy; Webster K Cavenee; Steven J Bensinger; Paul S Mischel
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

9.  Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.

Authors:  Michelle S Bradbury; Dolores Hambardzumyan; Pat B Zanzonico; Jazmin Schwartz; Shangde Cai; Eva M Burnazi; Valerie Longo; Steven M Larson; Eric C Holland
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

Review 10.  Genetically engineered mouse models of brain cancer and the promise of preclinical testing.

Authors:  Jason T Huse; Eric C Holland
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.